{"id":51717,"date":"2022-12-08T13:06:33","date_gmt":"2022-12-08T12:06:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/better-therapeutics-completes-exploratory-trial-for-fatty-liver-disease-and-announces-positive-topline-results\/"},"modified":"2022-12-08T13:06:33","modified_gmt":"2022-12-08T12:06:33","slug":"better-therapeutics-completes-exploratory-trial-for-fatty-liver-disease-and-announces-positive-topline-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/better-therapeutics-completes-exploratory-trial-for-fatty-liver-disease-and-announces-positive-topline-results\/","title":{"rendered":"Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results"},"content":{"rendered":"
\n

\nStudy Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients\n<\/p>\n

\nCompany Intends to Apply for Breakthrough Device Designation with FDA\n<\/p>\n

\nCompany to Host Conference Call and Webcast Today at 8:30 a.m. ET\n<\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc<\/a>. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced positive topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).\n<\/p>\n

<\/a><\/p>\n

\nThe study included a cohort of 22 patients with NAFLD and NASH and used Magnetic Resonance Imaging – Proton Density Fat Fraction (MRI-PDFF) scans, a validated proxy for liver biopsies, to monitor changes in liver fat. Changes in a range of exploratory liver biomarkers were also assessed. Currently, there is no FDA approved treatment for these conditions, which affect approximately one in four Americans<\/a> and cause approximately $100 billion in direct medical cost annually. And while some drug candidates are in various phases of research and development, they often present side effects that could limit their utility in patients, if approved.\n<\/p>\n

\n\u201cWith approximately 90 million Americans affected by NAFLD, fatty liver disease is a public health crisis that has hit epidemic levels. Because there are currently no FDA approved therapies available to treat these patients, we need to evaluate every possible option to reduce the burden of this condition \u2013 and in this study we have found positive topline signals across multiple disease biomarkers for a potential new option in our fight against NAFLD and NASH,\u201d said Mazen Noureddin, MD, Director of the Houston Liver Institute and who served as the Senior Scientific Advisor for the LivVita Study. \u201cSince the cause and progression of these conditions are linked to behavioral factors like diet and activity level, the utilization of a prescription digital therapy that targets these behaviors is compelling and appears to have the potential to make a real difference in this costly disease.\u201d\n<\/p>\n

\nThe LivVita Study met its primary endpoint, showing a statistically significant positive signal with an average relative reduction in MRI-PDFF of 16% (p=0.01) in the intent-to-treat population (N=19). Additional highlights include:\n<\/p>\n